Key Highlights

  • The Russell 2000 small-cap index underperformed with a 1.60 percent decline.
  • WillScot Holdings fell nearly 4 percent on debt-servicing concerns.
  • Ginkgo Bioworks dropped 3.64 percent amid the broader rate-sensitive selloff.
  • Biomea Fusion fell roughly 20 percent, driven by a stock offering rather than rate sensitivity alone.

Small-Caps Lead the Underperformance

The Russell 2000 small-cap index fell 1.60 percent on September 23, 2026, underperforming larger-cap indices as surging Treasury yields disproportionately pressured companies more reliant on external financing and floating-rate debt. Small-cap companies generally carry higher Leverage relative to their size and have less access to the kind of low-cost, long-duration financing available to larger, investment-grade issuers, making them structurally more vulnerable when borrowing costs rise quickly.

WillScot and the Debt-Servicing Angle

WillScot Holdings fell nearly 4 percent amid specific concerns about the company's debt-servicing costs as borrowing rates climbed, illustrating how individual companies with elevated leverage can see outsized stock-price reactions during periods of rising rates even when the broader Business fundamentals have not materially changed. Debt-servicing concerns of this kind tend to intensify when yields move quickly, since refinancing existing obligations at higher rates directly increases a company's interest expense and pressures free cash flow. The stock's 3.98 percent decline was tied specifically to concerns over elevated Debt leverage, declining unit utilization rates and broader industrial-sector headwinds. Biomea Fusion's roughly 20 percent drop was likewise company-specific, following the cancellation of a planned Equity offering and a delay of Phase 1 topline data for its oral GLP-1 candidate BMF-650 from the third quarter into October.

Biotech Names Add to the Decliner List

Ginkgo Bioworks fell 3.64 percent as part of the broader rate-sensitive selloff affecting growth-oriented biotech names, while Biomea Fusion dropped roughly 20 percent, though that decline was driven primarily by a dilutive stock offering rather than rate sensitivity alone. The combination of a genuine macro-driven selloff in select names alongside a company-specific capital-raise event in others illustrates how multiple distinct forces were compounding within the same broad group of decliners on the day.

Where Things Stand

The session's list of decliners, from small-cap benchmarks to individually leveraged names like WillScot and growth-stage biotechs like Ginkgo Bioworks, underscores how directly surging borrowing costs are reshaping which parts of the market face the greatest pressure. Continued yield increases would likely extend this pattern, keeping rate-sensitive and highly leveraged names in focus.